Annexon’s (ANNX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Annexon (NASDAQ:ANNX) in a report released on Friday morning,Benzinga reports. The firm currently has a $30.00 target price on the stock. HC Wainwright also issued estimates for Annexon’s FY2027 earnings at $0.49 EPS and FY2028 earnings at $0.90 EPS.

ANNX has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Monday, September 9th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Annexon in a report on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $15.80.

Annexon Trading Down 3.3 %

NASDAQ:ANNX opened at $6.12 on Friday. The company’s 50 day moving average is $6.91 and its two-hundred day moving average is $5.92. The company has a market cap of $646.58 million, a PE ratio of -5.83 and a beta of 1.23. Annexon has a twelve month low of $2.27 and a twelve month high of $8.40.

Insiders Place Their Bets

In other Annexon news, EVP Ted Yednock sold 5,500 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $5.64, for a total value of $31,020.00. Following the sale, the executive vice president now owns 10,000 shares in the company, valued at approximately $56,400. This represents a 35.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 20,908 shares of company stock valued at $135,768. Company insiders own 12.67% of the company’s stock.

Hedge Funds Weigh In On Annexon

Large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its holdings in Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after buying an additional 2,949 shares in the last quarter. Sandia Investment Management LP purchased a new position in shares of Annexon in the second quarter valued at approximately $49,000. Victory Capital Management Inc. purchased a new position in Annexon in the 2nd quarter valued at $51,000. Principal Financial Group Inc. acquired a new stake in Annexon during the 2nd quarter worth $56,000. Finally, Comerica Bank purchased a new stake in shares of Annexon during the first quarter worth $72,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.